Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Breast Neoplasms 6Colorectal Neoplasms 4Brain Neoplasms 3Radiodermatitis 2Pancreatic Neoplasms 2Pain, Postoperative 2Lung Neoplasms 2Leiomyoma 2Head and Neck Neoplasms 2Warts 1Surgical Wound 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Diseases 1Sigmoid Neoplasms 1Severe Acute Respiratory Syndrome 1Sarcoma 1Rectal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neuroinflammatory Diseases 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Mastocytosis 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Injury 1Locally Advanced Cervical Cancer 1Limited Stage Small Cell Lung Cancer 1

Interventions

Sodium Chloride 1BNT162 Vaccine 12019-nCoV Vaccine mRNA-1273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Severe Acute Respiratory Syndrome × Sodium Chloride × 1 year × Clear all
NCT04761822 2025-08-12

SARS

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
746 enrolled 28 charts
Myeloid

COVID-19, Hypersensitivity, Mastocytosis, Severe Acute Respiratory Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡